Clinical Trial Update: E-Selectin Nasal Instillation to Prevent Secondary Stroke [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating an E-Selectin nasal instillation to prevent secondary stroke was withdrawn before completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke
• Transient Ischemic Attack

Drugs mentioned

• E-Selectin nasal instillation

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Ischemic Attack, Transient, Transient | Phase 1 | Status: WITHDRAWN